See article by Fabritz et al. [1] (pages 500-508) in this issue.
In this issue of Cardiovascular Research, a paper by Fabritz et al. [1] investigates the effects of controlled overexpression of the A 3 adenosine receptor (A 3 AR) in the mouse heart. Their findings will feed further the current debate on the use of adenosine receptors (AR) as targets for gene therapy aimed at protecting the myocardium against ischemic damage. Furthermore, Fabritz et al. report interesting observations on the functional role of adenosine receptors in the regulation of heart rate.
Adenosine and cardioprotection
In the heart, adenosine regulates pacemaker activity as well as different cellular functions through the A1, A 2 , and A 3 AR. ARs are expressed on different cell types, including myocytes, vascular and endothelial cells, fibroblasts, and neutrophils (for review, see Ref. [2] ). Furthermore, adenosine activates the cellular mechanisms of protection from ischemic damage. Endogenous release of adenosine during myocardial ischemia induces a potent protective effect in both a paracine and autocrine way [3] . Particularly, adenosine reduces the infarct size and delays the onset of ischemic contracture by reducing the rate of ATP catabolism. It also improves the postischemic contractile function and attenuates myocardial stunning. At the cellular level, adenosine induces cardioprotection by directly acting on cardiomyocytes, by inhibiting platelet aggregation and adhesion of inflammatory cells to the endothelium, and by reducing the production of superoxide by neutrophils [3, 4] . Administration of adenosine is effective in both ischemic and pharmacological preconditioning [5] and throughout the early [6] and delayed [7] windows of preconditioning.
Gene therapy and AR
The observation that exogenous administration of adenosine has antiischemic properties during coronary angioplasty has suggested the possibility of developing clinical therapies that mimic adenosine-dependent cardioprotection [8] . However, the use of AR agonists in clinical settings is complicated by the side effects of the drugs on extracardiac tissue and by progressive desensitization of receptors for high doses of adenosine [9] . Second, even if the stimulation of endogenous AR does induce cardioprotection, the high extracellular level of adenosine reached during ischemia can reduce the efficacy of systemic administration of AR agonists [10, 11] . To overcome these limitations, research on gene therapy has focused on the overexpression of AR for enhancing the receptor density coupled to intracellular signalling pathways responsible for cardioprotection [11] . Choice of the A 1 AR or the A 3 AR for developing candidate transgenes is of importance. Indeed, differences exist in the properties of cardioprotection observed when A 1 AR and A 3 AR receptors are stimulated. For example, pharmacological stimulation of the A 3 AR by specific agonist induces sustained protection as compared to stimulation of the A 1 AR receptor, which is less long lasting [12] . The development of a transgenic mouse model in which the expression of the A 3 AR has been enhanced is thus an important step toward the development of cardioprotective gene therapy. However, given the functional importance of ARs in the regulation of the heartbeat, possible complications of the use of the A 1 AR or A 3 AR receptor for gene therapy may arise. Indeed, we can expect consequences for heart rhythm and conduction due to overexpression of ARs also in the sinoatrial node (SAN) and the conduction centres of the heart: the atrioventricular (AV) node and the Purkinje fibres. This point is particularly relevant, because changes in heart rhythm and rate can lead to serious alterations in myocardial contractility and performance.
These expectations have been confirmed to some extent by a previous study dealing with a transgenic mouse line overexpressing the A 1 AR in the heart [11, 13] . These mice have shown that both the heart rate and susceptibility to ischemic damage are affected in A 1 AR transgenic mice. Here, overexpression by about 1000-fold of the A 1 AR induced SAN bradycardia in transgenic animals. In contrast, no change in heart contractility and coronary function was observed, indicating that cardiac A 1 AR overexpression may not have deleterious effects on heart performance. Furthermore, transgenic hearts showed increased time to ischemic contracture as well as improved functional recovery after reperfusion. However, mice overexpressing the A 1 AR also showed partial AV block and increased susceptibility to episodes of atrial arrhythmias when challenged with exogenous adenosine [13] . These studies have thus supported the hypothesis of the usefulness of the manipulation of AR expression for cardiac gene therapy, but they have also highlighted the necessity to moderate receptor expression.
In this respect, the work by Fabritz et al. [1] constitutes a promising step in this direction. Indeed, this group has specifically investigated the cardiac phenotype of two mouse lines expressing low (A 3 low ) and high (A 3 high ) amounts of the A 3 AR. When compared to the A 3 low mice, the A 3 high mouse line shows about fivefold higher A 3 AR density. By extending previous observations on the same mice [14] , Fabritz et al. show that low expression of the A 3 AR has almost no detrimental effect on the transgenic hearts except for a slight slowing of the AV conduction. In addition, A 3 low transgenic hearts show a significant increase in cardioprotection as assessed by an ischemia -reperfusion protocol [14] . In contrast, high expression of the A 3 AR in A 3 high mice leads to a complex phenotype that includes SAN bradycardia, bradycardia-tachycardia syndrome, and complete AV block. In addition, A 3 high mice develop severe cardiomyopathy, possibly as a consequence of the chronic atrioventricular block and incessant supraventricular arrhythmia. The phenotype of the A 3 high mice is of particular interest, because establishment of atrial arrhythmias during the first postnatal weeks precedes the onset of cardiomyopathy, which then progressively worsens during adulthood. End-stage A 3 high hearts display atrial dilatation, structural and biochemical remodelling, fibrosis, and ventricular contractile dysfunction. It is thus tempting to suggest that the A 3 high mouse constitute a promising mouse model for studying in vivo the mechanisms of progression from chronic supraventricular arrhythmias to heart failure and, more generally, the mechanisms of cardiac structural remodelling linked to chronic rhythm dysfunctions.
Perspectives for the study of heart rate regulation
Interestingly, A 3 high mice described by Fabritz et al.
[1] also display constitutive antiadrenergic effects mediated by ARs. Indeed, in A 3 high mice both bradycardia and AV block cannot be relieved by h-adrenergic receptor stimulation. This rather surprising observation is strongly suggestive of a high tonic activation of inwardly rectifiying K + currents, such as I KACh . Furthermore, it is also possible that A 3 AR can control the heart rate in vivo by interacting with different G-proteins, each interaction inducing a particular effect on heart rate. A 3 AR could thus act with G i to prevent elevation of intracellular cAMP or with G q to activate I KACh . The phenotype of A 3 high mice seems to support these hypotheses, since both constitutive antiadrenergic effect and tonic AV block are observed. In addition, comparison of findings from A 3 high mice with previous results from mice overexpressing the A 1 AR [13] , mice in which h-adrenergic stimulation did reverse bradycardia and AV-block, indicates that the A 1 AR and A 3 AR exert different types of control of heart rate. Thus, the study of the functional role of these receptors in heart rate regulation is of much interest.
Conclusions
In summary, recent studies such as that by Fabritz et al. [1] show that it is possible to significantly improve the resistance of the heart to ischemic damage by increasing the expression of A 3 AR without detrimental side effects on heart rate and systolic function. This work also indicates unequivocally that the possibility of a successful gene therapy will be critically dependent on a tight control of the level of expression of A 3 AR. However, it would also be interesting to study cardioprotection in mice expressing the A 3 AR specifically in the ventricle. The A 3 AR is expressed in the human heart [15] . Gene therapy approaches might thus consider targeting A 3 AR expression to the ventricle. Such specificity should also help in limiting the possible side effects of overexpressing the A 3 AR in the atrium as well as in the SAN and AV node. In addition, the progressive cardiomyopathy developed by A 3 high mice further stress the tight physiological link existing between heart rhythm, cardiac pathology, and cardioprotection.
